U.K. study finds mRNA COVID-19 vaccines provide biggest booster impact

COVID-19 vaccines made by Pfizer and Moderna that use mRNA technology provide the biggest boost to antibody levels when given 10-12 weeks after the second dose, a British study published on Thursday has found.

The COV-Booststudy was cited by British officials when they announced that Pfizer and Moderna were preferred for use in the country's booster campaign, but the data has only been made publicly available now.

The study found that six out of the seven boosters examined enhanced immunity after initial vaccination with Pfizer-BioNTech's vaccine, while all seven increased immunity when given after two doses of AstraZeneca's vaccine.

"A third dose will be effective for many of the vaccines we've tested and in many different combinations," Prof. Saul Faust, an immunologist at the University of Southampton and the trial's lead, told reporters.

The study found that a full dose or half dose of Pfizer or a full dose of Moderna gave a very effective boost to both antibody and T-cell levels, regardless of whether the person initially received Pfizer or AstraZeneca.

When AstraZeneca, Novavax, Johnson & Johnson and Curevac were given as boosters, they increased antibody levels for either initial vaccine, albeit to a smaller degree. However, while Valneva boosted antibodies in people initially vaccinated with AstraZeneca, it did not provide a boost for Pfizer.

What's the latest on boosters?

WATCH |Eligibility for COVID-19 booster shots varies across Canada:

Eligibility for COVID-19 booster shots varies across Canada

3 years ago

Duration 2:03

Ontario will lower the eligibility age for COVID-19 booster shots to 50 and up by mid-December, adding to a shifting map of booster shot eligibility in Canada. There are calls for provinces and territories to be more cohesive with each other on who gets a booster shot.

The study found that booster shots also helped to generate a broad T-cell response against the beta and delta variants, which may play a key role in longer-term protection.

"T-cell (response) does seem to be broader against all the variant strains, which gives us hope that a variant strain of the virus might be able to be handled, certainly hospitalization and death, if not prevention of infection, by the current vaccines," Faust said.

The study pre-dated the spread of the omicron variant of concern, but Faust said he had shared samples with the UK Health Security Agency to generate data on omicron as well.